Perrigo Ends Patent Fight With GSK Unit, Will Be Allowed to Sell Generic Skin Drug

Allegan, Mich.-based Perrigo Co. June 11 said it had settled patent litigation with Stiefel Research Australia Pty. Ltd., a GlaxoSmithKline unit, over Perrigo’s application to market a generic version of the skin medication Olux-E (clobetasol propionate emulsion foam, .05 percent) (Stiefel Research Australia Pty. Ltd. v. Perrigo Israel Pharmaceuticals Ltd.).

In a June 11 release, Perrigo said it will be allowed to sell its generic clobetasol propionate foam .05 percent in the United States on Feb. 1, 2013, or earlier under certain circumstances.

Perrigo was the first applicant to submit a substantially complete abbreviated new drug application (ANDA) ...